Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $100KOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Germano Geno J | Director | Mar 09 '26 | Buy | $1.30 | 20,000 | $26,000 | 40,000 | Mar 11 08:30 AM |
Company profile
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Ellis Sean |
| Director |
| Mar 05 '26 |
| Buy |
| $1.23 |
| 10,000 |
| $12,300 |
| 188,098 |
| Mar 09 08:30 AM |
| Rubin Steven D | Director | Feb 12 '26 | Buy | $1.49 | 5,000 | $7,450 | 15,000 | Feb 17 08:30 AM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.